Медикаментозное лечение аденомиоза. Обзор литературы

1. Оразов М.Р., Радзинский В.Е., Хамошина М.Б., и др. Эффективность комплексной терапии тазовой боли, ассоциированной с аденомиозом. Трудный пациент. 2020;18(4):34-40 [Orazov MR, Radzinskiy VE, Khamoshina MB, et al. Effectiveness of Complex Therapy of Pelvic Pain Associated with Adenomyosis. Difficult Patient. 2020;18(4):34-40 (in Russian)]. DOI:10.24411/2074-1995-2020-10028
2. Давыдов А.И., Таирова М.Б., Михалева Л.М., и др. Аденомиоз. Что изменилось с появлением МКБ-11? Вопросы гинекологии, акушерства и перинатологии. 2021;20(2):117-24 [Davydov AI, Tairova MB, Mikhaleva LM, et al. Adenomyosis. What Has Changed Since The Advent of ICD-11? Vopr. ginekol. akus. perinatol. (Gynecology, Obstetrics and Perinatology). 2021;20(2):117-24 (in Russian)]. DOI:10.20953/1726-1678-2021-2-117-124
3. Moawad G, Kheil MH, Ayoubi JM, et al. Adenomyosis and infertility. J Assist Reprod Genet. 2022;39(5):1027-31. DOI:10.1007/s10815-022-02476-2
4. Donnez J, Stratopoulou CA, Dolmans MM. Uterine Adenomyosis: From Disease Pathogenesis to a New Medical Approach Using GnRH Antagonists. Int J Environ Res Public Health. 2021;18(19):9941. DOI:10.3390/ijerph18199941
5. Szubert M, Koziróg E, Olszak O, et al. Adenomyosis and Infertility-Review of Medical and Surgical Approaches. Int J Environ Res Public Health. 2021;18(3):1235. DOI:10.3390/ijerph18031235
6. Schrager S, Yogendran L, Marquez CM, Sadowski EA. Adenomyosis: Diagnosis and Management. Am Fam Physician. 2022;105(1):33-8.
7. Vannuccini S, Petraglia F. Recent advances in understanding and managing adenomyosis. F1000Res. 2019;8:F1000 Faculty Rev-283. DOI:10.12688/f1000research.17242.1
8. Chapron C, Vannuccini S, Santulli P, et al. Diagnosing adenomyosis: an integrated clinical and imaging approach. Hum Reprod Update. 2020;26(3):392-411. DOI:10.1093/humupd/dmz049
9. Orlov S, Jokubkiene L. Prevalence of endometriosis and adenomyosis at transvaginal ultrasound examination in symptomatic women. Acta Obstet Gynecol Scand. 2022;101(5):524-31. DOI:10.1111/aogs.14337
10. Pontis A, D'Alterio MN, Pirarba S, et al. Adenomyosis: a systematic review of medical treatment. Gynecol Endocrinol. 2016;32(9):696-700. DOI:10.1080/09513590.2016.1197200
11. Vannuccini S, Luisi S, Tosti C, et al. Role of medical therapy in the management of uterine adenomyosis. Fertil Steril. 2018;109(3):398-405. DOI:10.1016/j.fertnstert.2018.01.013
12. Baboo KD, Chen Z, Zhang X. Progress on medical treatment in the management of adenomyosis. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2019;48(2):142-7. DOI:10.3785/j.issn.1008-9292.2019.04.04
13. Marjoribanks J, Ayeleke RO, Farquhar C, Proctor M. Nonsteroidal anti-inflammatory drugs for dysmenorrhoea. Cochrane Database Syst Rev. 2015;2015(7):CD001751. DOI:10.1002/14651858.CD001751.pub3
14. Lethaby A, Augood C, Duckitt K, Farquhar C. Nonsteroidal anti-inflammatory drugs for heavy menstrual bleeding. Cochrane Database Syst Rev. 2007;(4):CD000400. DOI:10.1002/14651858.CD000400.pub2
15. Bofill Rodriguez M, Lethaby A, Farquhar C. Non-steroidal anti-inflammatory drugs for heavy menstrual bleeding. Cochrane Database Syst Rev. 2019;9(9):CD000400. DOI:10.1002/14651858.CD000400.pub4
16. Cope AG, Ainsworth AJ, Stewart EA. Current and Future Medical Therapies for Adenomyosis. Semin Reprod Med. 2020;38(2-03):151-6. DOI:10.1055/s-0040-1719016
17. Li L, Leng J, Jia S, Lang J. Treatment of symptomatic adenomyosis with the levonorgestrel-releasing intrauterine system. Int J Gynaecol Obstet. 2019;146(3):357-63. DOI:10.1002/ijgo.12887
18. Park DS, Kim ML, Song T, et al. Clinical experiences of the levonorgestrel-releasing intrauterine system in patients with large symptomatic adenomyosis. Taiwan J Obstet Gynecol. 2015;54(4):412-5. DOI:10.1016/j.tjog.2014.05.009
19. Rathinam KK, Abraham JJ, S HP, et al. Evaluation of pharmacological interventions in the management of adenomyosis: a systematic review. Eur J Clin Pharmacol. 2022;78(4):531-45. DOI:10.1007/s00228-021-03256-0
20. Chen S, Wang J, Sun W, et al. Efficacy of the levonorgestrel-releasing intrauterine device is associated with different subtypes of adenomyosis: a retrospective study. Ann Transl Med. 2020;8(21):1356. DOI:10.21037/atm-20-3420
21. Badawy AM, Elnashar AM, Mosbah AA. Aromatase inhibitors or gonadotropin-releasing hormone agonists for the management of uterine adenomyosis: a randomized controlled trial. Acta Obstet Gynecol Scand. 2012;91(4):489-95. DOI:10.1111/j.1600-0412.2012.01350.x
22. Ferrero S, Gillott DJ, Venturini PL, Remorgida V. Use of aromatase inhibitors to treat endometriosis-related pain symptoms: a systematic review. Reprod Biol Endocrinol. 2011;9:89. DOI:10.1186/1477-7827-9-89
23. Benetti-Pinto CL, Mira TAA, Yela DA, et al. Pharmacological Treatment for Symptomatic Adenomyosis: A Systematic Review. Tratamento farmacológico para adenomiose sintomática: revisão sistemática. Rev Bras Ginecol Obstet. 2019;41(9):564-74. DOI:10.1055/s-0039-1695737
24. Kobayashi H. Molecular Targets for Nonhormonal Treatment Based on a Multistep Process of Adenomyosis Development. Reprod Sci. 2023;30(3):743-60. DOI:10.1007/s43032-022-01036-4
25. Lin J, Ma H, Li H, et al. The Treatment of Complementary and Alternative Medicine on Female Infertility Caused by Endometrial Factors. Evid Based Complement Alternat Med. 2022;2022:4624311. DOI:10.1155/2022/4624311
26. Ebert AD, Макаренко Т.А., Цхай В.Б., и др. Альтернативные методы лечения эндометриоза: Ресвератрол и его комбинация с гормонотерапией. Сибирское медицинское обозрение. 2018;2:106-8 [Ebert AD, Makarenko TA, Tskhay VB, et al. Alternative Methods of Treatment of Endometriosis: Resveratrol and its Combination with Hormonotherapy. Siberian Medical Review. 2018;2:106-8 (in Russian)]. DOI:10.20333/2500136-2018-2-106-108
27. Brown J, Farquhar C. Endometriosis: an overview of Cochrane Reviews. Cochrane Database Syst Rev. 2014;2014(3):CD009590. DOI:10.1002/14651858.CD009590.pub2
28. Ulrich U, Buchweitz O, Greb R, et al. National German Guideline (S2k): Guideline for the Diagnosis and Treatment of Endometriosis: Long Version – AWMF Registry No. 015-045. Geburtshilfe Frauenheilkd. 2014;74(12):1104-18. DOI:10.1055/s-0034-1383187
29. Хашукоева А.З., Хлынова С.А., Ильина И.Ю., Керчелаева С.А. Эстрогензависимые состояния женской репродуктивной системы: возможности негормональной терапии с применением индол-3-карбинола. Акушерство и гинекология. 2020;5:65-9 [Khashukoeva AZ, Khlynova SA, Ilyina IYu, Kerchelaeva SB. Estrogen-dependent Conditions of the Female Reproductive System: Possibilities of Nonhormonal Therapy Using Indole-3-carbinol. Obstetrics and Gynecology. 2020;5:65-9 (in Russian)]. DOI:10.18565/aig.2020.5.65-69
30. Давыдов А.И., Чилова Р.А., Лебедев В.А., Таирова М.Б. Аденомиоз и оксидативный стресс. Обоснование комплексного подхода к лечению пациенток репродуктивного возраста. Вопросы гинекологии, акушерства и перинатологии. 2021;20(6):155-61 [Davydov AI, Chilova RA, Lebedev VA, Tairova MB. Adenomyosis and Oxidative Stress. Rationale for Comprehensive Approach to Treatment of Patients of Reproductive Age. Vopr. ginekol. akus. perinatol. (Gynecology, Obstetrics and Perinatology). 2021;20(6):155-61 (in Russian)]. DOI:10.20953/1726-1678-2021-6-155-161
31. Ярмолинская М.И., Хачатурян А.Р., Андреева Н.Ю., Пьянкова В.О. Современные возможности и перспективы применения пероральной формы антагонистов гонадотропин-рилизинг-гормона (обзор литературы). Проблемы репродукции. 2020;26(5):78-83 [Yarmolinskaya MI, Khachaturyan AR, Andreeva NYu, Pyankova VO. The Oral Gonadotropin-releasing Hormone Antagonists: Contemporary Possibilities and Perspectives of Application. Russian Journal of Human Reproduction. 2020;26(5):78-83 (in Russian)]. DOI:10.17116/repro20202605178
32. Zhang K, Zhou Z, Wang C, et al. Mechanism Study of Cinnamomi Ramulus and Paris polyphylla Sm. Drug Pair in the Treatment of Adenomyosis by Network Pharmacology and Experimental Validation. Evid Based Complement Alternat Med. 2022;2022:2624434. DOI:10.1155/2022/2624434
33. Клинические рекомендации «Эндометриоз». М.: РОАГ, 2020 [Klinicheskiie rekomendatsii "Endometrios". Moscow: ROAG, 2020 (in Russian)].
34. Chen I, Veth VB, Choudhry AJ, et al. Pre- and postsurgical medical therapy for endometriosis surgery. Cochrane Database Syst Rev. 2020;11(11):CD003678. DOI:10.1002/14651858.CD003678.pub
35. Hassanin AI, Youssef AA, Yousef AM, Ali MK. Comparison of dienogest versus combined oral contraceptive pills in the treatment of women with adenomyosis: A randomized clinical trial. Int J Gynaecol Obstet. 2021;154(2):263-9. DOI:10.1002/ijgo.13600
36. Hirata T, Izumi G, Takamura M, et al. Efficacy of dienogest in the treatment of symptomatic adenomyosis: a pilot study. Gynecol Endocrinol. 2014;30(10):726-9. DOI:10.3109/09513590.2014.926882
37. Ono N, Asano R, Nagai K, et al. Evaluating the safety of dienogest in women with adenomyosis: A retrospective analysis. J Obstet Gynaecol Res. 2021;47(4):1433-40. DOI:10.1111/jog.14612
38. Neriishi K, Hirata T, Fukuda S, et al. Long-term dienogest administration in patients with symptomatic adenomyosis. J Obstet Gynaecol Res. 2018;44(8):1439-44. DOI:10.1111/jog.13674
39. Lazaridis A, Grammatis AL, Spencer S, Hirsch M. Nonsurgical management of adenomyosis: an overview of current evidence. Curr Opin Obstet Gynecol. 2022;34(5):315-23. DOI:10.1097/GCO.0000000000000810
40. Schweppe KW. The place of dydrogesterone in the treatment of endometriosis and adenomyosis. Maturitas. 2009;65(Suppl. 1):S23-7. DOI:10.1016/j.maturitas.2009.11.011
41. Sun S, Zhang H, Zhong P, Xu Z. The Effect of Letrozole Combined with Dydrogesterone for Endometriosis in China: A Meta-Analysis. Biomed Res Int. 2021;2021:9946060. DOI:10.1155/2021/9946060
42. Сухих Г.Т., Адамян Л.В., Козаченко А.В., и др. Дидрогестерон для лечения подтвержденного эндометриоза: ключевые результаты наблюдательного открытого многоцентрового исследования в условиях реальной клинической практики. Акушерство и гинекология. Новости. Мнения. Обучение. 2020;8(4):79-81 [Sukhikh GT, Adamyan LV, Kozachenko AV, et al. Dydrogesterone for the Treatment of Confirmed Endometriosis: Key Findings from an Observational Open Multicentre Study in a Real Clinical Setting. Obstetrics And Gynecology. News. Views. Education. 2020;8(4):79-81 (in Russian)]. DOI:10.24411/2303-9698-2020-14006
43. Беженарь В.Ф., Круглов С.Ю., Кузьмина Н.С., и др. Целесообразность длительной гормональной терапии эндометриоза после хирургического лечения. Акушерство и гинекология. 2021;4:134-42 [Bezhenar VF, Kruglov SYu, Kuzmina NS, et al. Effectiveness of Long-term Hormone Therapy for Endometriosis After Surgical Treatment. Obstetrics and Gynecology. 2021;4:134-42 (in Russian)]. DOI:10.18565/aig.2021.4.134-142
44. Stratopoulou CA, Donnez J, Dolmans MM. Conservative Management of Uterine Adenomyosis: Medical vs. Surgical Approach. J Clin Med. 2021;10(21):4878. DOI:10.3390/jcm10214878 
45. Borini A, Coticchio G. Gonadotropin-releasing hormone antagonist linzagolix: possible treatment for assisted reproduction patients presenting with adenomyosis and endometriosis? Fertil Steril. 2020;114(3):517-8. DOI:10.1016/j.fertnstert.2020.06.003 
46. Donnez O, Donnez J. Gonadotropin-releasing hormone antagonist (linzagolix): a new therapy for uterine adenomyosis. Fertil Steril. 2020;114(3):640-5. DOI:10.1016/j.fertnstert.2020.04.017
47. Gracia M, Alcalà M, Ferreri J, et al. Ulipristal Acetate Improves Clinical Symptoms in Women with Adenomyosis and Uterine Myomas. J Minim Invasive Gynecol. 2018;25(7):1274-80. DOI:10.1016/j.jmig.2018.04.002
48. Andreeva E, Absatarova Y. Triptorelin for the treatment of adenomyosis: A multicenter observational study of 465 women in Russia. Int J Gynaecol Obstet. 2020;151(3):347-54. DOI:10.1002/ijgo.13341
49. Tskhay V, Schindler AE, Мikailly G. Operation, hormone therapy and recovery of the patients with severe forms of adenomyosis. Gynecol Endocrinol. 2018;34(8):647-50. DOI:10.1080/09513590.2017.1397116
50. Цхай В.Б. Аденомиоз. Контраверсии современности. Боли. Кровотечения. Бесплодие. Под ред. В.Е. Радзинского. М.: Status Praesens, 2020 [Tskhay VB. Adenomios. Kontraversii sovremennosti. Pod red. VE Radzinskogo. Moscow: Status Praesens, 2020 (in Russian)].
51. Matsushima T, Akira S, Yoneyama K, Takeshita T. Recurrence of uterine adenomyosis after administration of gonadotropin-releasing hormone agonist and the efficacy of dienogest. Gynecol Endocrinol. 2020;36(6):521-4. DOI:10.1080/09513590.2019.1683818
52. Che X, Wang J, He J, et al. The new application of mifepristone in the relief of adenomyosis-caused dysmenorrhea. Int J Med Sci. 2020;17(2):224-33. DOI:10.7150/ijms.39252
53. Che X, Wang J, He J, et al. A new trick for an old dog: The application of mifepristone in the treatment of adenomyosis. J Cell Mol Med. 2020;24(2):1724-37. DOI:10.1111/jcmm.14866 
54. Tsui KH, Lee WL, Chen CY, et al. Medical treatment for adenomyosis and/or adenomyoma. Taiwan J Obstet Gynecol. 2014;53(4):459-65. DOI:10.1016/j.tjog.2014.04.024
55. Soave I, Wenger JM, Pluchino N, Marci R. Treatment options and reproductive outcome for adenomyosis-associated infertility. Curr Med Res Opin. 2018;34(5):839-49. DOI:10.1080/03007995.2017.1393404
56. Rocha TP, Andres MP, Borrelli GM, Abrão MS. Fertility-Sparing Treatment of Adenomyosis in Patients With Infertility: A Systematic Review of Current Options. Reprod Sci. 2018;25(4):480-6. DOI:10.1177/1933719118756754
57. Sharara FI, Kheil MH, Feki A, et al. Current and Prospective Treatment of Adenomyosis. J Clin Med. 2021;10(15):3410. DOI:10.3390/jcm10153410

________________________________________________

1. Orazov MR, Radzinskiy VE, Khamoshina MB, et al. Effectiveness of Complex Therapy of Pelvic Pain Associated with Adenomyosis. Difficult Patient. 2020;18(4):34-40 (in Russian). DOI:10.24411/2074-1995-2020-10028
2. Davydov AI, Tairova MB, Mikhaleva LM, et al. Adenomyosis. What Has Changed Since The Advent of ICD-11? Vopr. ginekol. akus. perinatol. (Gynecology, Obstetrics and Perinatology). 2021;20(2):117-24 (in Russian). DOI:10.20953/1726-1678-2021-2-117-124
3. Moawad G, Kheil MH, Ayoubi JM, et al. Adenomyosis and infertility. J Assist Reprod Genet. 2022;39(5):1027-31. DOI:10.1007/s10815-022-02476-2
4. Donnez J, Stratopoulou CA, Dolmans MM. Uterine Adenomyosis: From Disease Pathogenesis to a New Medical Approach Using GnRH Antagonists. Int J Environ Res Public Health. 2021;18(19):9941. DOI:10.3390/ijerph18199941
5. Szubert M, Koziróg E, Olszak O, et al. Adenomyosis and Infertility-Review of Medical and Surgical Approaches. Int J Environ Res Public Health. 2021;18(3):1235. DOI:10.3390/ijerph18031235
6. Schrager S, Yogendran L, Marquez CM, Sadowski EA. Adenomyosis: Diagnosis and Management. Am Fam Physician. 2022;105(1):33-8.
7. Vannuccini S, Petraglia F. Recent advances in understanding and managing adenomyosis. F1000Res. 2019;8:F1000 Faculty Rev-283. DOI:10.12688/f1000research.17242.1
8. Chapron C, Vannuccini S, Santulli P, et al. Diagnosing adenomyosis: an integrated clinical and imaging approach. Hum Reprod Update. 2020;26(3):392-411. DOI:10.1093/humupd/dmz049
9. Orlov S, Jokubkiene L. Prevalence of endometriosis and adenomyosis at transvaginal ultrasound examination in symptomatic women. Acta Obstet Gynecol Scand. 2022;101(5):524-31. DOI:10.1111/aogs.14337
10. Pontis A, D'Alterio MN, Pirarba S, et al. Adenomyosis: a systematic review of medical treatment. Gynecol Endocrinol. 2016;32(9):696-700. DOI:10.1080/09513590.2016.1197200
11. Vannuccini S, Luisi S, Tosti C, et al. Role of medical therapy in the management of uterine adenomyosis. Fertil Steril. 2018;109(3):398-405. DOI:10.1016/j.fertnstert.2018.01.013
12. Baboo KD, Chen Z, Zhang X. Progress on medical treatment in the management of adenomyosis. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2019;48(2):142-7. DOI:10.3785/j.issn.1008-9292.2019.04.04
13. Marjoribanks J, Ayeleke RO, Farquhar C, Proctor M. Nonsteroidal anti-inflammatory drugs for dysmenorrhoea. Cochrane Database Syst Rev. 2015;2015(7):CD001751. DOI:10.1002/14651858.CD001751.pub3
14. Lethaby A, Augood C, Duckitt K, Farquhar C. Nonsteroidal anti-inflammatory drugs for heavy menstrual bleeding. Cochrane Database Syst Rev. 2007;(4):CD000400. DOI:10.1002/14651858.CD000400.pub2
15. Bofill Rodriguez M, Lethaby A, Farquhar C. Non-steroidal anti-inflammatory drugs for heavy menstrual bleeding. Cochrane Database Syst Rev. 2019;9(9):CD000400. DOI:10.1002/14651858.CD000400.pub4
16. Cope AG, Ainsworth AJ, Stewart EA. Current and Future Medical Therapies for Adenomyosis. Semin Reprod Med. 2020;38(2-03):151-6. DOI:10.1055/s-0040-1719016
17. Li L, Leng J, Jia S, Lang J. Treatment of symptomatic adenomyosis with the levonorgestrel-releasing intrauterine system. Int J Gynaecol Obstet. 2019;146(3):357-63. DOI:10.1002/ijgo.12887
18. Park DS, Kim ML, Song T, et al. Clinical experiences of the levonorgestrel-releasing intrauterine system in patients with large symptomatic adenomyosis. Taiwan J Obstet Gynecol. 2015;54(4):412-5. DOI:10.1016/j.tjog.2014.05.009
19. Rathinam KK, Abraham JJ, S HP, et al. Evaluation of pharmacological interventions in the management of adenomyosis: a systematic review. Eur J Clin Pharmacol. 2022;78(4):531-45. DOI:10.1007/s00228-021-03256-0
20. Chen S, Wang J, Sun W, et al. Efficacy of the levonorgestrel-releasing intrauterine device is associated with different subtypes of adenomyosis: a retrospective study. Ann Transl Med. 2020;8(21):1356. DOI:10.21037/atm-20-3420
21. Badawy AM, Elnashar AM, Mosbah AA. Aromatase inhibitors or gonadotropin-releasing hormone agonists for the management of uterine adenomyosis: a randomized controlled trial. Acta Obstet Gynecol Scand. 2012;91(4):489-95. DOI:10.1111/j.1600-0412.2012.01350.x
22. Ferrero S, Gillott DJ, Venturini PL, Remorgida V. Use of aromatase inhibitors to treat endometriosis-related pain symptoms: a systematic review. Reprod Biol Endocrinol. 2011;9:89. DOI:10.1186/1477-7827-9-89
23. Benetti-Pinto CL, Mira TAA, Yela DA, et al. Pharmacological Treatment for Symptomatic Adenomyosis: A Systematic Review. Tratamento farmacológico para adenomiose sintomática: revisão sistemática. Rev Bras Ginecol Obstet. 2019;41(9):564-74. DOI:10.1055/s-0039-1695737
24. Kobayashi H. Molecular Targets for Nonhormonal Treatment Based on a Multistep Process of Adenomyosis Development. Reprod Sci. 2023;30(3):743-60. DOI:10.1007/s43032-022-01036-4
25. Lin J, Ma H, Li H, et al. The Treatment of Complementary and Alternative Medicine on Female Infertility Caused by Endometrial Factors. Evid Based Complement Alternat Med. 2022;2022:4624311. DOI:10.1155/2022/4624311
26. Ebert AD, Макаренко Т.А., Цхай В.Б., и др. Альтернативные методы лечения эндометриоза: Ресвератрол и его комбинация с гормонотерапией. Сибирское медицинское обозрение. 2018;2:106-8 [Ebert AD, Makarenko TA, Tskhay VB, et al. Alternative Methods of Treatment of Endometriosis: Resveratrol and its Combination with Hormonotherapy. Siberian Medical Review. 2018;2:106-8 (in Russian)]. DOI:10.20333/2500136-2018-2-106-108
27. Brown J, Farquhar C. Endometriosis: an overview of Cochrane Reviews. Cochrane Database Syst Rev. 2014;2014(3):CD009590. DOI:10.1002/14651858.CD009590.pub2
28. Ulrich U, Buchweitz O, Greb R, et al. National German Guideline (S2k): Guideline for the Diagnosis and Treatment of Endometriosis: Long Version – AWMF Registry No. 015-045. Geburtshilfe Frauenheilkd. 2014;74(12):1104-18. DOI:10.1055/s-0034-1383187
29. Khashukoeva AZ, Khlynova SA, Ilyina IYu, Kerchelaeva SB. Estrogen-dependent Conditions of the Female Reproductive System: Possibilities of Nonhormonal Therapy Using Indole-3-carbinol. Obstetrics and Gynecology. 2020;5:65-9 (in Russian). DOI:10.18565/aig.2020.5.65-69
30. Davydov AI, Chilova RA, Lebedev VA, Tairova MB. Adenomyosis and Oxidative Stress. Rationale for Comprehensive Approach to Treatment of Patients of Reproductive Age. Vopr. ginekol. akus. perinatol. (Gynecology, Obstetrics and Perinatology). 2021;20(6):155-61 (in Russian). DOI:10.20953/1726-1678-2021-6-155-161
31. Yarmolinskaya MI, Khachaturyan AR, Andreeva NYu, Pyankova VO. The Oral Gonadotropin-releasing Hormone Antagonists: Contemporary Possibilities and Perspectives of Application. Russian Journal of Human Reproduction. 2020;26(5):78-83 (in Russian). DOI:10.17116/repro20202605178
32. Zhang K, Zhou Z, Wang C, et al. Mechanism Study of Cinnamomi Ramulus and Paris polyphylla Sm. Drug Pair in the Treatment of Adenomyosis by Network Pharmacology and Experimental Validation. Evid Based Complement Alternat Med. 2022;2022:2624434. DOI:10.1155/2022/2624434
33. Клинические рекомендации «Эндометриоз». М.: РОАГ, 2020 [Klinicheskiie rekomendatsii "Endometrios". Moscow: ROAG, 2020 (in Russian)].
34. Chen I, Veth VB, Choudhry AJ, et al. Pre- and postsurgical medical therapy for endometriosis surgery. Cochrane Database Syst Rev. 2020;11(11):CD003678. DOI:10.1002/14651858.CD003678.pub
35. Hassanin AI, Youssef AA, Yousef AM, Ali MK. Comparison of dienogest versus combined oral contraceptive pills in the treatment of women with adenomyosis: A randomized clinical trial. Int J Gynaecol Obstet. 2021;154(2):263-9. DOI:10.1002/ijgo.13600
36. Hirata T, Izumi G, Takamura M, et al. Efficacy of dienogest in the treatment of symptomatic adenomyosis: a pilot study. Gynecol Endocrinol. 2014;30(10):726-9. DOI:10.3109/09513590.2014.926882
37. Ono N, Asano R, Nagai K, et al. Evaluating the safety of dienogest in women with adenomyosis: A retrospective analysis. J Obstet Gynaecol Res. 2021;47(4):1433-40. DOI:10.1111/jog.14612
38. Neriishi K, Hirata T, Fukuda S, et al. Long-term dienogest administration in patients with symptomatic adenomyosis. J Obstet Gynaecol Res. 2018;44(8):1439-44. DOI:10.1111/jog.13674
39. Lazaridis A, Grammatis AL, Spencer S, Hirsch M. Nonsurgical management of adenomyosis: an overview of current evidence. Curr Opin Obstet Gynecol. 2022;34(5):315-23. DOI:10.1097/GCO.0000000000000810
40. Schweppe KW. The place of dydrogesterone in the treatment of endometriosis and adenomyosis. Maturitas. 2009;65(Suppl. 1):S23-7. DOI:10.1016/j.maturitas.2009.11.011
41. Sun S, Zhang H, Zhong P, Xu Z. The Effect of Letrozole Combined with Dydrogesterone for Endometriosis in China: A Meta-Analysis. Biomed Res Int. 2021;2021:9946060. DOI:10.1155/2021/9946060
42. Sukhikh GT, Adamyan LV, Kozachenko AV, et al. Dydrogesterone for the Treatment of Confirmed Endometriosis: Key Findings from an Observational Open Multicentre Study in a Real Clinical Setting. Obstetrics And Gynecology. News. Views. Education. 2020;8(4):79-81 (in Russian). DOI:10.24411/2303-9698-2020-14006
43. Bezhenar VF, Kruglov SYu, Kuzmina NS, et al. Effectiveness of Long-term Hormone Therapy for Endometriosis After Surgical Treatment. Obstetrics and Gynecology. 2021;4:134-42 (in Russian). DOI:10.18565/aig.2021.4.134-142
44. Stratopoulou CA, Donnez J, Dolmans MM. Conservative Management of Uterine Adenomyosis: Medical vs. Surgical Approach. J Clin Med. 2021;10(21):4878. DOI:10.3390/jcm10214878 
45. Borini A, Coticchio G. Gonadotropin-releasing hormone antagonist linzagolix: possible treatment for assisted reproduction patients presenting with adenomyosis and endometriosis? Fertil Steril. 2020;114(3):517-8. DOI:10.1016/j.fertnstert.2020.06.003 
46. Donnez O, Donnez J. Gonadotropin-releasing hormone antagonist (linzagolix): a new therapy for uterine adenomyosis. Fertil Steril. 2020;114(3):640-5. DOI:10.1016/j.fertnstert.2020.04.017
47. Gracia M, Alcalà M, Ferreri J, et al. Ulipristal Acetate Improves Clinical Symptoms in Women with Adenomyosis and Uterine Myomas. J Minim Invasive Gynecol. 2018;25(7):1274-80. DOI:10.1016/j.jmig.2018.04.002
48. Andreeva E, Absatarova Y. Triptorelin for the treatment of adenomyosis: A multicenter observational study of 465 women in Russia. Int J Gynaecol Obstet. 2020;151(3):347-54. DOI:10.1002/ijgo.13341
49. Tskhay V, Schindler AE, Мikailly G. Operation, hormone therapy and recovery of the patients with severe forms of adenomyosis. Gynecol Endocrinol. 2018;34(8):647-50. DOI:10.1080/09513590.2017.1397116
50. Tskhay VB. Adenomios. Kontraversii sovremennosti. Pod red. VE Radzinskogo. Moscow: Status Praesens, 2020 (in Russian).
51. Matsushima T, Akira S, Yoneyama K, Takeshita T. Recurrence of uterine adenomyosis after administration of gonadotropin-releasing hormone agonist and the efficacy of dienogest. Gynecol Endocrinol. 2020;36(6):521-4. DOI:10.1080/09513590.2019.1683818
52. Che X, Wang J, He J, et al. The new application of mifepristone in the relief of adenomyosis-caused dysmenorrhea. Int J Med Sci. 2020;17(2):224-33. DOI:10.7150/ijms.39252
53. Che X, Wang J, He J, et al. A new trick for an old dog: The application of mifepristone in the treatment of adenomyosis. J Cell Mol Med. 2020;24(2):1724-37. DOI:10.1111/jcmm.14866 
54. Tsui KH, Lee WL, Chen CY, et al. Medical treatment for adenomyosis and/or adenomyoma. Taiwan J Obstet Gynecol. 2014;53(4):459-65. DOI:10.1016/j.tjog.2014.04.024
55. Soave I, Wenger JM, Pluchino N, Marci R. Treatment options and reproductive outcome for adenomyosis-associated infertility. Curr Med Res Opin. 2018;34(5):839-49. DOI:10.1080/03007995.2017.1393404
56. Rocha TP, Andres MP, Borrelli GM, Abrão MS. Fertility-Sparing Treatment of Adenomyosis in Patients With Infertility: A Systematic Review of Current Options. Reprod Sci. 2018;25(4):480-6. DOI:10.1177/1933719118756754
57. Sharara FI, Kheil MH, Feki A, et al. Current and Prospective Treatment of Adenomyosis. J Clin Med. 2021;10(15):3410. DOI:10.3390/jcm10153410

В.Б. Цхай*1,2, А.А. Бакунина1, Г.Т. Микаиллы1

1 ФГБОУ ВО «Красноярский государственный медицинский университет им. проф. В.Ф. Войно-Ясенецкого» Минздрава России, Красноярск, Россия;
2 ФГБУ «Федеральный Сибирский научно-клинический центр» ФМБА России, Красноярск, Россия
*tchai@yandex.ru

________________________________________________

Vitaly B. Tskhay*1,2, Anna A. Bakunina1, Gulnar T. Mikailli1

1 Voyno-Yasenetsky Krasnoyarsk State Medical University, Krasnoyarsk, Russia;
2 Federal Siberian Research and Clinical Centre, Krasnoyarsk, Russia
*tchai@yandex.ru